- Home
- JAZZ
as 06-20-2025 4:00pm EST
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
| Founded: | 2003 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN |
| Market Cap: | 6.7B | IPO Year: | 2007 |
| Target Price: | $183.08 | AVG Volume (30 days): | 730.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.51 | EPS Growth: | 49.21 |
| 52 Week Low/High: | $95.49 - $148.06 | Next Earning Date: | 07-30-2025 |
| Revenue: | $4,064,808,000 | Revenue Growth: | 5.76% |
| Revenue Growth (this year): | 6.05% | Revenue Growth (next year): | 4.68% |
Stock Insider Trading Activity of Jazz Pharmaceuticals plc (Ireland) (JAZZ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| COZADD BRUCE C | JAZZ | Chairman & CEO | Jun 2 '25 | Sell | $108.95 | 1,000 | $108,950.00 | 437,973 | |
| Mulligan Seamus | JAZZ | Director | May 9 '25 | Buy | $99.93 | 101,621 | $9,993,081.71 | 99,900 | |
| COZADD BRUCE C | JAZZ | Chairman & CEO | May 1 '25 | Sell | $118.18 | 1,500 | $176,350.00 | 437,973 | |
| COZADD BRUCE C | JAZZ | Chairman & CEO | Apr 1 '25 | Sell | $123.75 | 1,500 | $185,625.00 | 437,973 |
Latest Jazz Pharmaceuticals plc (Ireland) News
JAZZ Breaking Stock News: Dive into JAZZ Ticker-Specific Updates for Smart Investing
Insider Monkey
9 days ago
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®
Argus Research
10 days ago
JAZZ: Raising target price to $124.00
MT Newswires
11 days ago
Jazz Pharmaceuticals Says Zepzelca-Tecentriq Combination Gets FDA Priority Review for Lung Cancer Treatment
PR Newswire
11 days ago
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
MT Newswires
11 days ago
Jazz Pharmaceuticals Says Narcolepsy Drug Meets Primary Endpoint in Phase 4 Trial
PR Newswire
11 days ago
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
Zacks
16 days ago
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
PR Newswire
19 days ago
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Compare JAZZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAZZ Jazz Pharmaceuticals plc (Ireland) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.